Exelixis Unveils Additional Data on Cabometyx for Neuroendocrine Tumors
Citi Maintains Exelixis(EXEL.US) With Buy Rating, Maintains Target Price $31
Citi analyst David Lebovitz maintains $Exelixis(EXEL.US)$ with a buy rating, and maintains the target price at $31.According to TipRanks data, the analyst has a success rate of 50.2% and a total
Exelixis (EXEL) Gets a Hold From Stifel Nicolaus
Wells Fargo Maintains Exelixis(EXEL.US) With Buy Rating, Maintains Target Price $32
Wells Fargo analyst Derek Archila maintains $Exelixis(EXEL.US)$ with a buy rating, and maintains the target price at $32.According to TipRanks data, the analyst has a success rate of 48.3% and a
H.C. Wainwright Maintains Exelixis(EXEL.US) With Buy Rating, Maintains Target Price $29
H.C. Wainwright analyst Robert Burns maintains $Exelixis(EXEL.US)$ with a buy rating, and maintains the target price at $29.According to TipRanks data, the analyst has a success rate of 30.9% and a
Exelixis (EXEL) Stock Buy Rating Affirmed on Promising Subgroup Data and Market Opportunity in MCRPC Treatment